Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 18/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15872107 | 1.00 | FKBP1A (0.77) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL15872099 | 0.95 | FKBP1A (0.84) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL18233883 | 0.94 | FKBP1A (0.88) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL437534 | 0.93 | FKBP1A (0.81) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL437462 | 0.93 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL436555 | 0.92 | ABCB11 (0.88) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL439484 | 0.92 | ABCB11 (0.88) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL469099 | 0.91 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL16907274 | 0.90 | FKBP1A (0.74) | FKBP1AMEN1LMNAMAPTKMT2A | |
| SCHEMBL13173685 | 0.90 | FKBP1A (0.90) | FKBP1AMEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000514-B2 | Antifungal compounds | DUKE UNIVERSITY (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200188364-A1 | ANTIFUNGAL COMPOUNDS | DUKE UNIVERSITY | 2020-06-18 | — | — | US | disclosed |
| US-10568872-B2 | Antifungal compounds | DUKE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190000814-A1 | Antifungal Compounds | AMPLYX PHARMACEUTICALS, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-9956207-B2 | Antifungal compounds | AMPLYX PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9956207-B2 | Antifungal compounds | AMPLYX PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20160331730-A1 | Antifungal Compounds | AMPLYX PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160331730-A1 | Antifungal Compounds | AMPLYX PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015106283-A1 | ANTIFUNGAL COMPOUNDS | AMPLYX PHARMACEUTICALS, INC. (US) | 2015-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160331730-A1 | Antifungal Compounds | ERG28, DPM1, CYP51A1 | FKBP1A 997/4885MEN1 749/4885LMNA 2924/4885 |
| US-10568872-B2 | Antifungal compounds | ERG28, DPM1, CYP51A1 | FKBP1A 997/4885MEN1 749/4885LMNA 2924/4885 |
| US-20190000814-A1 | Antifungal Compounds | ERG28, DPM1, CYP51A1 | FKBP1A 997/4885MEN1 749/4885LMNA 2924/4885 |
| US-11000514-B2 | Antifungal compounds | ERG28, DPM1, CYP51A1 | FKBP1A 997/4885MEN1 749/4885LMNA 2924/4885 |
| US-20200188364-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | FKBP1A 997/4885MEN1 749/4885LMNA 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.